A detailed history of Susquehanna Fundamental Investments, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 15,899 shares of SUPN stock, worth $413,850. This represents 0.03% of its overall portfolio holdings.

Number of Shares
15,899
Holding current value
$413,850
% of portfolio
0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$27.11 - $35.17 $431,021 - $559,167
15,899 New
15,899 $542 Million
Q1 2023

May 16, 2023

SELL
$34.93 - $42.03 $293,272 - $352,883
-8,396 Reduced 15.1%
47,212 $1.71 Million
Q4 2022

Feb 14, 2023

SELL
$31.09 - $37.88 $131,510 - $160,232
-4,230 Reduced 7.07%
55,608 $1.98 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $1.2 Million - $1.48 Million
41,852 Added 232.69%
59,838 $2.03 Million
Q1 2022

May 16, 2022

BUY
$28.51 - $32.9 $512,780 - $591,739
17,986 New
17,986 $581,000
Q3 2021

Nov 15, 2021

SELL
$23.54 - $31.39 $390,481 - $520,697
-16,588 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$26.72 - $33.19 $317,059 - $393,832
-11,866 Reduced 41.7%
16,588 $511,000
Q1 2021

May 17, 2021

BUY
$24.15 - $31.45 $372,127 - $484,613
15,409 Added 118.12%
28,454 $745,000
Q4 2020

Feb 16, 2021

SELL
$17.7 - $25.81 $61,153 - $89,173
-3,455 Reduced 20.94%
13,045 $328,000
Q3 2020

Nov 16, 2020

BUY
$20.2 - $25.05 $20,200 - $25,050
1,000 Added 6.45%
16,500 $344,000
Q2 2020

Aug 14, 2020

BUY
$17.09 - $24.89 $264,895 - $385,795
15,500 New
15,500 $368,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.39B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.